早期宫颈癌微创与开腹根治性子宫切除术的长期肿瘤结局与复发模式:挪威镭医院经验
单中心回顾性研究纳入2000–2017年582例FIGO 2009 IA1–IB1期宫颈癌根治性子宫切除术患者,其中开腹353例、微创229例。在IB1期患者中,校正标准预后变量后,微创组复发风险为开腹组的2.73倍(95%CI 1.56–4.80),且癌症特异性生存和总生存亦更差;微创组腹腔内合并复发占复发的40.0%,开腹组未见。
要点
- IB1期宫颈癌微创根治术复发风险为开腹组的2.73倍(95%CI 1.56–4.80)。
- IB1期≤2 cm且未行锥切者,微创组至复发时间亦显著缩短(HR 4.00)。
- 微创组腹腔内合并复发占40.0%,开腹组未观察到(p=0.0001)。
核心结论
- 在IB1期宫颈癌患者中,微创根治性子宫切除术较开腹手术与更短的至复发时间、更差的癌症特异性生存和总生存相关。
- 微创组腹腔内复发风险高,即使肿瘤≤2 cm且未行锥切者亦然。
研究设计与样本
- 单中心回顾性研究,纳入2000–2017年FIGO 2009 IA1–IB1期鳞癌、腺癌及腺鳞癌根治性子宫切除术患者582例。
- 开腹组353例(60.7%),微创组229例(39.3%);开腹组中位随访14.4年,微创组6.1年(p<0.0001)。
主要发现
- 96例IA期患者中仅3例(3.1%)复发。
- IB1期患者校正标准预后变量后,微创组复发风险为开腹组2.73倍(HR 2.73,95%CI 1.56–4.80),癌症特异性生存HR 3.04(95%CI 1.28–7.20),总生存HR 2.35(95%CI 1.21–4.59)。
- IB1期≤2 cm且未行锥切者,微创组至复发时间HR 4.00(95%CI 1.67–9.57),癌症特异性生存HR 3.71(95%CI 1.19–11.58),总生存HR 3.02(95%CI 1.24–7.34)。
- 微创组30例复发中12例(40.0%)为腹腔内合并复发,开腹组未发现(p=0.0001)。
临床怎么用
- 对IB1期宫颈癌,尤其肿瘤≤2 cm且未行锥切者,选择微创根治性子宫切除术需充分告知腹腔内复发风险及生存劣势。
- 术后随访应关注腹腔内复发模式,微创术后患者尤需警惕。
局限性
- 单中心回顾性设计,开腹组与微创组中位随访时间差异显著(14.4年 vs 6.1年,p<0.0001)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare long-term oncological outcomes in early-stage cervical cancer (CC) patients treated with minimally invasive radical hysterectomy (MIRH) versus abdominal radical hysterectomy (ARH), with a focus on recurrence patterns, tumor sizes, and conization. METHODS: This single-institution, retrospective study consisted of stage IA1-IB1 (FIGO 2009) squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the cervix, who underwent radical hysterectomy between 2000 and 2017. RESULTS: Of the 582 patients included, 353 (60.7%) underwent ARH, and 229 (39.3%) MIRH. The median follow-up was 14.4 years in the ARH group and 6.1 years in the MIRH group (p < 0.0001). Among the 96 stage IA patients, only 3 (3.1%) experienced recurrence. Among stage IB1 patients, the risk of recurrence, after adjusting for standard prognostic variables, was twofold higher in the MIRH group versus the ARH group (HR 2.73, 95% CI: 1.56-4.80), and the relative difference was similar in terms of risk of cancer-specific survival (CSS) (HR 3.04, 95% CI: 1.28-7.20) and overall survival (OS) (HR 2.35, 95% CI: 1.21-4.59). In stage IB1 ≤ 2 cm patients without conization MIRH was associated with reduced time to recurrence (TTR) (HR 4.00, 95% CI: 1.67-9.57), CSS (HR 3.71, 95% CI: 1.19-11.58) and OS (HR 3.02, 95% CI: 1.24-7.34). Intraperitoneal combined recurrences accounted for 12 of 30 (40.0%) recurrences in the MIRH group but were not identified after ARH (p = 0.0001). CONCLUSIONS: MIRH was associated with reduced TTR, CSS and OS versus ARH in stage IB1 CC patients. The risk of peritoneal recurrence was high, even for tumors ≤2 cm without conization.
引用
- Sert BM, Kristensen GB, Kleppe A, et al. Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience. Gynecol Oncol. 2021. PMID: 34083029. doi:10.1016/j.ygyno.2021.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。